enGene Holdings Inc

ENGN07 Feb 2025
Healthcare
$6.93
-0.08 (-7.97%)
Lowest Today
$6.06
Highest Today
$7.18
Today’s Open
$6.93
Prev. Close
$6.9
52 Week High
$18.4
52 Week Low
$4.42
To Invest in enGene Holdings Inc

enGene Holdings Inc

Healthcare
ENGN07 Feb 2025
-0.08 (-7.97%)
1M
3M
6M
1Y
5Y
Low
$6.06
Day’s Range
High
$7.18
6.06
52 Week Low
$4.42
52-Week Range
52 Week High
$18.4
4.42
1 Day
-
1 Week
-6.36%
1 month return
-19.26%
3 month return
-24.82%
6 month return
-9.89%
1 Year return
-17.47%
3 Years return
-36.06%
5 Years return
-
10 Years return
-

Market Status

Fundamentals
Market Cap
351.74 mln
PB Ratio
1.29
PE Ratio
0
Enterprise Value
138.43 mln
Total Assets
311.17 mln
Volume

Company Financials

Fund house & investment objective

Company Information
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.
Organisation
enGene Holdings Inc
Employees
31
Industry
Biotechnology
CEO
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities